5-Amino-1MQ
NNMT inhibitor
5-Amino-1MQ is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT) that has shown fat-reduction effects in mouse and cell studies, with essentially no published human evidence.
Regulatory status: Not an approved drug. It is a laboratory research compound with no FDA or other regulatory approval, and no peer-reviewed human clinical trial data were located.
Default vial
50 mg
Default mix
2 mL
Reported range
50–150 mg (oral), 25–50 mg (injectable)
Draw (U-100)
200 u
Small-molecule NNMT inhibitor, most often taken as an oral capsule in the morning; injectable use is far less standardized. Dosing conventions vary widely — the numbers here are community reference points only.
What it is
- A cell-permeable small-molecule inhibitor of nicotinamide N-methyltransferase, an enzyme implicated in fat-cell and liver energy metabolism.
- A synthetic quinolinium-based enzyme inhibitor — not a peptide, unlike most of this library.
- Studied preclinically by oral or intraperitoneal dosing in rodents rather than as an injected peptide.
- Proposed to raise cellular NAD+ and SAM-pathway metabolites by blocking NNMT-mediated nicotinamide methylation.
How it is described to act
- 1
In preclinical studies it was given orally or intraperitoneally to rodents and reported to be absorbed systemically.
- 2
Proposed to reach adipose and liver tissue, where NNMT is highly expressed.
- 3
Hypothesised to inhibit NNMT enzymatic activity, altering nicotinamide, NAD+ and polyamine metabolic flux — a pathway established mainly through genetic knockdown work.
- 4
In mouse models this was associated with reduced adiposity and improved metabolic markers; no evidence was located that this carries over to people.
What the research has looked at
Genetic foundation for the target
- Kraus et al. (Nature, 2014) reported that knocking down NNMT in adipose and liver tissue protected mice against diet-induced obesity, establishing NNMT as a metabolic drug target. This is knockdown evidence about the enzyme, not evidence about 5-Amino-1MQ in people.
Small-molecule inhibitor work
- Studies of NNMT-targeting small molecules have reported enzyme-inhibitory and anti-proliferative activity in cell models (2021), supporting proof of concept for pharmacological NNMT inhibition without demonstrating human obesity outcomes.
Strength of evidence: Preclinical evidence only
The evidence consists of rodent and cell-culture studies of NNMT inhibition; no peer-reviewed human clinical data were located, making this one of the least clinically validated entries in the library.
What is published comes from cell and animal studies. Findings in those models frequently do not carry over to people.
Reported cautions and unknowns
- No human safety or adverse-event data exist in the peer-reviewed literature located, because no formal human trials or regulatory review have taken place.
- The broader NNMT literature raises theoretical concerns about off-target inhibition in other tissues, including the liver; these have not been quantified for this compound in humans.
- Pregnancy and long-term organ-toxicity data are entirely unestablished, so safety claims in commercial listings are not supported by the sources reviewed.
References
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
5-Amino-1MQ questions people ask
How do you reconstitute 5-Amino-1MQ?
A common starting point for a 50 mg vial of 5-Amino-1MQ is 2 mL of bacteriostatic water, which gives 25 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of 5-Amino-1MQ is one dose?
At 25 mg per mL, that works out to about 200 units on a U-100 insulin syringe for a 50000 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for 5-Amino-1MQ?
Published and community sources describe 50–150 mg (oral), 25–50 mg (injectable), oral capsule / subcutaneous, every day, typically run 8 weeks on and 4 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should 5-Amino-1MQ be stored?
Lyophilized 5-Amino-1MQ vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.